Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

44.40USD
10 Dec 2018
Change (% chg)

-- (--)
Prev Close
$44.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,050,883
52-wk High
$46.47
52-wk Low
$33.20

Latest Key Developments (Source: Significant Developments)

Abbvie Announces Humira Global Patent License With Pfizer
Friday, 30 Nov 2018 10:00am EST 

Nov 30 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES HUMIRA (ADALIMUMAB) GLOBAL PATENT LICENSE WITH PFIZER.PFIZER WILL PAY ROYALTIES TO ABBVIE FOR LICENSING ITS HUMIRA PATENTS AND ACKNOWLEDGES VALIDITY OF LICENSED PATENTS.ABBVIE WILL MAKE NO PAYMENTS TO PFIZER.WILL GRANT PFIZER A NON-EXCLUSIVE LICENSE ON SPECIFIED DATES TO ABBVIE'S INTELLECTUAL PROPERTY RELATING TO HUMIRA.  Full Article

Pfizer Reaches A Global Agreement With AbbVie
Friday, 30 Nov 2018 10:00am EST 

Nov 30 (Reuters) - Pfizer Inc ::PFIZER REACHES A GLOBAL AGREEMENT WITH ABBVIE.ALL INTELLECTUAL PROPERTY MATTERS FOR PFIZER'S PROPOSED ADALIMUMAB BIOSIMILAR RESOLVED.IN UNITED STATES, LICENSE PERIOD WILL BEGIN ON NOVEMBER 20, 2023.ALL LITIGATION PENDING BETWEEN PARTIES WILL BE WITHDRAWN.FINANCIAL DETAILS OF AGREEMENTS ARE CONFIDENTIAL..PFIZER MAY LAUNCH ITS ADALIMUMAB BIOSIMILAR UPON APPROVAL BY EUROPEAN MEDICINES AGENCY IN EUROPE.ABBVIE GRANTS CO A NON-EXCLUSIVE PATENT LICENSE FOR USE AND SALE OF CO'S PROPOSED ADALIMUMAB BIOSIMILAR FOR MANY COUNTRIES AROUND WORLD.SIGNED LICENSING AGREEMENTS WITH ABBVIE.  Full Article

Jianke.Com Enters Into Strategic Cooperation With Pfizer
Thursday, 29 Nov 2018 06:29am EST 

Nov 29 (Reuters) - Pfizer Inc ::JIANKE.COM ENTERS INTO STRATEGIC COOPERATION WITH PFIZER.  Full Article

Pfizer Receives Six Months Pediatric Exclusivity For Lyrica
Tuesday, 27 Nov 2018 03:01pm EST 

Nov 27 (Reuters) - Pfizer Inc ::PFIZER RECEIVES SIX MONTHS PEDIATRIC EXCLUSIVITY FOR LYRICA® (PREGABALIN).PFIZER - FDA'S GRANT EXTENDS PERIOD OF U.S. MARKET EXCLUSIVITY FOR LYRICA BY ADDITIONAL SIX MONTHS TO JUNE 30, 2019.  Full Article

Aileron Enters Clinical Trial Collaboration With Pfizer
Tuesday, 27 Nov 2018 08:00am EST 

Nov 27 (Reuters) - Aileron Therapeutics Inc ::AILERON ENTERS CLINICAL TRIAL COLLABORATION WITH PFIZER TO EVALUATE ALRN-6924 IN COMBINATION WITH IBRANCE® (PALBOCICLIB) IN MDM2-AMPLIFIED CANCERS.AILERON THERAPEUTICS INC - AILERON EXPECTS THIS PHASE 1B TRIAL TO START ENROLLING PATIENTS WITH SOLID TUMORS IN Q1 OF 2019.AILERON THERAPEUTICS INC - PFIZER WILL PROVIDE DRUG SUPPLY IN SUPPORT OF TRIAL.  Full Article

FDA Approves Pfizer's Daurismo Tablets For Treating Patients With Acute Myeloid Leukemia
Wednesday, 21 Nov 2018 12:51pm EST 

Nov 21 (Reuters) - U.S. Food and Drug Administration::FDA APPROVES NEW TREATMENT FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA.FDA SAYS PRESCRIBING INFORMATION FOR DAURISMO INCLUDES A BOXED WARNING.FDA SAYS APPROVED DAURISMO (GLASDEGIB) TABLETS TO BE USED IN COMBINATION WITH LOW-DOSE CYTARABINE FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA.FDA SAYS DAURISMO SHOULD NOT BE USED DURING PREGNANCY OR WHILE BREASTFEEDING.FDA - GRANTED APPROVAL OF DAURISMO TO PFIZER.FDA SAYS BOXED WARNING ALSO ADVISES MALE PATIENTS OF POTENTIAL RISK OF DRUG EXPOSURE THROUGH SEMEN.  Full Article

Zenith Epigenetics Enters Clinical Trial Collaboration With Pfizer
Tuesday, 20 Nov 2018 08:30am EST 

Nov 20 (Reuters) - Zenith Epigenetics Ltd::ZENITH EPIGENETICS ANNOUNCES CLINICAL TRIAL COLLABORATION WITH PFIZER.ZENITH EPIGENETICS - ENTERED A CLINICAL TRIAL COLLABORATION WITH PFIZER INC.ZENITH EPIGENETICS - CO AND PFIZER WILL COLLABORATE ON A PHASE 1B/2 TNBC CLINICAL STUDY.ZENITH EPIGENETICS - PFIZER WILL PROVIDE TALAZOPARIB, ZENITH WILL PROVIDE ZEN-3694, AND BOTH PARTIES WILL FUND STUDY.  Full Article

Merck And Pfizer Provide Update On Avelumab In Platinum-Resistant/Refractory Ovarian Cancer
Monday, 19 Nov 2018 07:12am EST 

Nov 19 (Reuters) - Merck KGaA ::MERCK AND PFIZER PROVIDE UPDATE ON AVELUMAB IN PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER.MERCK KGAA - SIGNALS WERE OBSERVED IN THE COMBINATION ARM RELATIVE TO PLD, AND FURTHER ANALYSES OF TRIAL ARE WARRANTED.MERCK - PHASE III JAVELIN OVARIAN 200 TRIAL DID NOT MEET PRESPECIFIED PRIMARY ENDPOINTS.MERCK KGAA - NO NEW SAFETY SIGNALS WERE OBSERVED FOR AVELUMAB ALONE OR IN COMBINATION.MERCK KGAA - SAFETY PROFILE FOR AVELUMAB IN TRIAL WAS CONSISTENT WITH OBSERVED IN OVERALL JAVELIN CLINICAL DEVELOPMENT PROGRAM.MERCK - STUDY RESULTS INDICATE POTENTIAL CLINICAL ACTIVITY OF COMBINATION OF AVELUMAB & CHEMOTHERAPY.  Full Article

Merck KGaA Phase III Javelin Ovarian 200 Trial Did Not Reach Endpoints
Monday, 19 Nov 2018 07:08am EST 

Nov 19 (Reuters) - Merck Kgaa AND PFIZER ::PHASE III JAVELIN OVARIAN 200 TRIAL EVALUATING AVELUMAB* ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD), DID NOT MEET PRESPECIFIED PRIMARY ENDPOINTS OF OVERALL SURVIVAL (OS) OR PROGRESSION-FREE SURVIVAL (PFS) IN PATIENTS WITH PLATINUM-RESISTANT OR -REFRACTORY OVARIAN CANCER.DATA ARE CURRENTLY BEING ANALYZED, AND DETAILED RESULTS WILL BE SHARED WITH SCIENTIFIC COMMUNITY.RESEARCHER SAYS ALTHOUGH OS AND PFS DID NOT REACH STATISTICAL SIGNIFICANCE, STUDY RESULTS INDICATE POTENTIAL CLINICAL ACTIVITY OF COMBINATION OF AVELUMAB AND CHEMOTHERAPY WHICH WILL BE ANALYZED FURTHER.  Full Article

Pfizer Q3 Earnings Per Share $0.69
Tuesday, 30 Oct 2018 06:45am EDT 

Oct 30 (Reuters) - Pfizer Inc ::PFIZER REPORTS THIRD-QUARTER 2018 RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.78.Q3 EARNINGS PER SHARE $0.69.Q3 EARNINGS PER SHARE VIEW $0.75 -- THOMSON REUTERS I/B/E/S.NOW EXPECT TO REPURCHASE APPROXIMATELY $12 BILLION OF SHARES IN 2018.NARROWED CERTAIN 2018 FINANCIAL GUIDANCE RANGES..THIRD-QUARTER 2018 REVENUES TOTALED $13.3 BILLION, AN INCREASE OF $130 MILLION, OR 1%, COMPARED TO PRIOR-YEAR QUARTER.QTRLY REVENUES $13,298 MILLION VERSUS $13,168 MILLION.Q3 REVENUE VIEW $13.53 BILLION -- THOMSON REUTERS I/B/E/S.MIDPOINT OF UPDATED ADJUSTED DILUTED EPS GUIDANCE FOR 2018 RANGE OF $2.98 TO $3.02 IS UNCHANGED FROM JULY 2018.QTRLY WORLDWIDE TOTAL LYRICA REVENUE $1,132 MILLION VERSUS $1,150 MILLION REPORTED LAST YEAR.2018 GUIDANCE RANGE FOR REVENUES WAS NARROWED FROM A RANGE OF $53.0 TO $55.0 BILLION TO A RANGE OF $53.0 TO $53.7 BILLION.QTRLY WORLDWIDE PREVNAR FAMILY REVENUE $1,660 MILLION VERSUS $1,522 MILLION REPORTED LAST YEAR.SEES LOWER-THAN-ANTICIPATED ESSENTIAL HEALTH REVENUES FOR 2018.FY2018 EARNINGS PER SHARE VIEW $2.99, REVENUE VIEW $54.15 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY WORLDWIDE IBRANCE REVENUE $1,025 MILLION VERSUS $878 MILLION REPORTED LAST YEAR.UPDATED 2018 GUIDANCE DUE TO RECENT UNFAVORABLE CHANGES IN FOREX RATES IN RELATION TO U.S. DOLLAR FROM MID-JULY 2018 TO MID-OCTOBER 2018.  Full Article

Allergan says tossing Pfizer lawsuit could endanger potential opioid accord

Allergan PLC says the chances of reaching a global settlement in the federal opioid litigation could be jeopardized if a judge dismisses a lawsuit seeking to force Pfizer Inc to indemnify it in cases involving a painkiller Allergan acquired from a company Pfizer owns.